PMID- 22125461
OWN - NLM
STAT- MEDLINE
DCOM- 20120327
LR  - 20211021
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 11
DP  - 2011
TI  - Advantages and disadvantages of hyperbaric oxygen treatment in mice with obesity 
      hyperlipidemia and steatohepatitis.
PG  - 2124-35
LID - 10.1100/2011/380236 [doi]
AB  - The effect of hyperbaric oxygen treatment (HBOT) was examined using MSG mice, 
      which are an animal model of obesity, hyperlipidemia, diabetes, and nonalcoholic 
      fatty liver disease. Nineteen MSG male mice were divided into HBOT treated and 
      control groups at 12 weeks of ages. The HBOT group was treated with hyperbaric 
      oxygen from 12 to 14 weeks (first phase) and then from 16 to 18 weeks (second 
      phase). Interestingly, the body weight of the HBOT group was significantly lower 
      (P < 0.01) than that of the control group. In contrast, the serum lipid level did 
      not show significant changes between the two groups. As for the effects of 
      increasing oxidative stress, the liver histology of the HBOT group showed severer 
      cellular damage and aberrant TNF-alpha expression. HBOT has the advantage of 
      improving obesity in patients with metabolic syndrome, but the fault of causing 
      organ damage by increasing oxidative stress.
FAU - Tsuneyama, Koichi
AU  - Tsuneyama K
AD  - Department of Diagnostic Pathology, Graduate School of Medicine and 
      Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
FAU - Chen, Yen-Chen
AU  - Chen YC
FAU - Fujimoto, Makoto
AU  - Fujimoto M
FAU - Sasaki, Yoshiyuki
AU  - Sasaki Y
FAU - Suzuki, Wataru
AU  - Suzuki W
FAU - Shimada, Tsutomu
AU  - Shimada T
FAU - Iizuka, Seiichi
AU  - Iizuka S
FAU - Nagata, Mitsunobu
AU  - Nagata M
FAU - Aburada, Masaki
AU  - Aburada M
FAU - Chen, Shao-Yuan
AU  - Chen SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111103
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Fatty Liver/complications/*therapy
MH  - *Hyperbaric Oxygenation
MH  - Hyperlipidemias/blood/complications/*therapy
MH  - Immunohistochemistry
MH  - Intra-Abdominal Fat/pathology
MH  - Liver/pathology
MH  - Male
MH  - Mice
MH  - Obesity/complications/*therapy
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC3217597
OTO - NOTNLM
OT  - MSG mice
OT  - Nonalcoholic steatohepatitis
OT  - hyperbaric oxygen treatment
OT  - obesity
EDAT- 2011/11/30 06:00
MHDA- 2012/03/28 06:00
PMCR- 2011/11/03
CRDT- 2011/11/30 06:00
PHST- 2011/08/30 00:00 [received]
PHST- 2011/10/15 00:00 [accepted]
PHST- 2011/11/30 06:00 [entrez]
PHST- 2011/11/30 06:00 [pubmed]
PHST- 2012/03/28 06:00 [medline]
PHST- 2011/11/03 00:00 [pmc-release]
AID - 10.1100/2011/380236 [doi]
PST - ppublish
SO  - ScientificWorldJournal. 2011;11:2124-35. doi: 10.1100/2011/380236. Epub 2011 Nov 
      3.